What it's for (Indications)
- Cephradine is a first-generation cephalosporin antibiotic utilized for the treatment of various bacterial infections.
- Its antibacterial spectrum predominantly covers Gram-positive cocci such as *Staphylococcus aureus* (including penicillinase-producing strains) and *Streptococcus pyogenes*, in addition to certain Gram-negative organisms like *Escherichia coli*, *Klebsiella species*, and *Proteus mirabilis*.
- It is commonly indicated for respiratory tract infections, including pharyngitis, tonsillitis, and lobar pneumonia, where susceptible organisms are identified or strongly suspected.
- Furthermore, it is effective in treating uncomplicated urinary tract infections, skin and soft tissue infections (e.
- g.
- , impetigo, cellulitis), and otitis media.
- The decision to initiate cephradine therapy should be based on culture and sensitivity results to ensure appropriate antimicrobial selection and to minimize the development of antibiotic resistance, promoting optimal patient outcomes and preventing the emergence of drug-resistant strains.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cephradine is highly dependent on the severity and type of infection, the patient's renal function, and their age and weight. For adults, typical oral dosages range from 250 mg to 500 mg administered every 6 to 12 hours. For more severe infections, doses may be increased or administered more frequently, adhering to established maximum daily limits. Pediatric dosing is usually calculated based on body weight, commonly in the range of 25-50 mg/kg/day divided into two to four equal doses, not exceeding the maximum adult dose. In patients with compromised renal function (e.g., creatinine clearance below 20-30 mL/min), a significant reduction in total daily dosage or a substantial increase in the dosing interval is imperative to prevent drug accumulation and potential systemic toxicity. Intravenous or intramuscular formulations are available for severe infections or when oral administration is not feasible, with dosages adjusted accordingly. It is crucial to adhere strictly to prescribed dosages and complete the full course of treatment, even if symptoms improve, to ensure complete eradication of the infection, prevent relapse, and mitigate the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Like all antibiotic agents, cephradine can cause a range of adverse effects, although most are mild, transient, and self-limiting.
- Common gastrointestinal disturbances frequently reported include nausea, vomiting, diarrhea, abdominal discomfort, and dyspepsia.
- Allergic reactions are also relatively common, manifesting as various dermatological presentations such as skin rashes, urticaria, pruritus, and drug fever.
- More severe, though rare, hypersensitivity reactions can occur, including Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and potentially life-threatening anaphylaxis.
- Hematological effects may include transient eosinophilia, leukopenia, neutropenia, and positive Coombs' tests, which typically resolve upon discontinuation of the drug.
- Renal adverse effects, though infrequent, can involve transient elevations in blood urea nitrogen (BUN) and serum creatinine, particularly in patients with pre-existing renal impairment or those receiving concomitant nephrotoxic agents.
- Superinfections, especially candidiasis (oral or vaginal) and *Clostridioides difficile*-associated diarrhea (CDAD), are potential complications arising from the alteration of normal microbial flora by broad-spectrum antibiotic use.
- Patients should be advised to report any persistent or severe side effects to their healthcare provider promptly for appropriate management.
Serious Warnings
- Black Box Warning: Cephradine does not have a specific FDA-mandated Black Box Warning. Black Box Warnings are reserved for medications that carry significant risks of serious or life-threatening adverse effects that necessitate prominent disclosure to healthcare providers and patients due to their severity or frequency. While cephradine is associated with serious potential adverse reactions such as severe hypersensitivity reactions (including anaphylaxis) and *Clostridioides difficile*-associated diarrhea (CDAD), these risks are generally well-documented and thoroughly addressed within the standard 'Warnings and Precautions' sections of its prescribing information, rather than requiring an explicit Black Box Warning. Healthcare professionals should nevertheless be acutely aware of these potential severe complications and counsel patients accordingly, especially regarding the symptoms of allergic reactions (e.g., rash, swelling, difficulty breathing) and the importance of reporting persistent or severe diarrhea. Careful patient selection, comprehensive allergy history assessment, and diligent renal function monitoring are critical components to minimize these inherent risks and ensure the safe and effective therapeutic use of cephradine.
- Although cephradine does not carry an FDA Black Box Warning, several serious adverse reactions warrant careful consideration and close monitoring during its administration.
- Hypersensitivity reactions, ranging from mild skin rashes to severe and potentially fatal anaphylaxis, have been reported with cephalosporin antibiotics, including cephradine.
- Patients with a known history of penicillin allergy should be closely monitored, as cross-reactivity between penicillins and cephalosporins occurs in approximately 5-10% of cases, with a higher risk for immediate-type hypersensitivity reactions.
- In such cases, cephradine should be used with extreme caution or avoided entirely.
- Furthermore, treatment with broad-spectrum antibiotics, including cephradine, can alter the normal gut flora and lead to the overgrowth of *Clostridioides difficile*, resulting in *Clostridioides difficile*-associated diarrhea (CDAD), which can range in severity from mild diarrhea to fatal pseudomembranous colitis.
- CDAD can occur more than two months after antibiotic discontinuation, necessitating careful evaluation of any diarrhea occurring post-treatment.
- Renal function should be meticulously monitored in patients with pre-existing renal impairment, as dosage adjustments are required to prevent drug accumulation and potential nephrotoxicity.
- Prolonged use may also lead to superinfections with non-susceptible organisms, highlighting the importance of appropriate treatment duration and microbial surveillance.
How it Works (Mechanism of Action)
Cephradine, as a first-generation cephalosporin antibiotic, exerts its potent bactericidal effect by selectively interfering with bacterial cell wall synthesis. As a beta-lactam antibiotic, its primary mechanism involves covalent binding to specific penicillin-binding proteins (PBPs) located on the inner membrane of the susceptible bacterial cell wall. PBPs are crucial enzymes, including transpeptidases, carboxypeptidases, and endopeptidases, which are fundamentally involved in the final stages of peptidoglycan synthesis. Peptidoglycan is a complex polymer essential for maintaining the structural integrity, rigidity, and osmotic stability of the bacterial cell wall. By binding to these PBPs, cephradine inhibits the transpeptidation reaction, which is responsible for the crucial cross-linking of peptidoglycan chains. This inhibition leads to a defect in cell wall formation, resulting in an accumulation of peptidoglycan precursors within the cell, activation of autolytic enzymes (autolysins) within the bacterial cell, progressive weakening of the cell wall structure, increased osmotic pressure, and ultimately, cell lysis and death of the bacterial organism. The selectivity of cephradine for bacterial PBPs over human enzymes accounts for its relative safety and efficacy in treating bacterial infections while minimizing host cell damage.